The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

R. Brown, Darron; K. Kjær, Susanne; Sigurðsson, Kristján; Iversen, Ole‐Erik; Hernández-Ávila, Mauricio; M. Wheeler, Cosette; Pérez, Gonzalo; A. Koutsky, Laura; Hseon Tay, Eng; García, Patricia; A. Ault, Kevin; M. Garland, Suzanne; Leodolter, Sepp; Olsson, Sven‐Eric; Tang, Grace; G. Ferris, Daron; Paavonen, Jorma; Steben, Marc; Xavier Bosch, F.; Dillner, Joakim; A. Joura, Elmar; J. Kurman, Robert; Majewski, Sławomir; Muñóz, Nubia; R. Myers, Evan; L. Villa, Luisa; J. Taddeo, Frank; C. Roberts, Christine; Tadesse, Amha; T. Bryan, Janine; Lupinacci, Lisa; Giacoletti, Katherine; L. Sings, Heather; K. James, Margaret; M. Hesley, Teresa; Barr, Eliav

doi:10.1086/597307

Public

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

Published in The Journal of Infectious Diseases • Feb 23, 2009

Authors:

Darron R. Brown

Susanne K. Kjær

Kristján Sigurðsson

Abstract

BACKGROUND: Human papillomavirus (HPV)-6/11/16/18 vaccine reduces the risk of HPV-6/11/16/18-related cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS). Here, its impact on CIN1-3/AIS associated with nonvaccine oncogenic HPV types was evaluated. METHODS: We enrolled 17,622 ...

Subject

Medicine

Cervical cancer

Cervical intraepithelial neoplasia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!